TGFBR2 and hepatocellular carcinoma: Deletion of TAK1 in hepatocytes elevated TGF-β signaling via the type II receptor (TGFβR2) and phospho-Smad2/3, contributing to liver fibrosis, inflammation, and the development of HCC (Yang et al., 2013).